tbuckley/cabot-search huggingface dataset:
Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses
Authors: H. Hammad, B. N. Lambrecht
Journal: Allergy (2011)

Because they can recognize and sample inhaled allergens, dendritic cells (DC) have been shown to be responsible for the initiation and maintenance of adaptive Th2 responses in asthma. It is increasingly clear that DC functions are strongly influenced by a crosstalk with neighboring cells like epithelial cells. Whereas the epithelium was initially considered only as a barrier, it is now seen as a central player in controlling the function of lung DCs through release of innate cytokines-promoting Th2 responses. Clinically relevant allergens, as well as known environmental and genetic risk factors for allergy and asthma, often interfere directly or indirectly with the innate immune functions of airway epithelial cells and DC. A better understanding of these interactions might lead to a better prevention and ultimately to new treatments for asthma.
Abstract 18468: Serum Hepcidin Predicts New Onset Heart Failure in Women in the Community
Authors: IJsbrand T Klip, Adriaan A Voors, Dirk J van Veldhuisen, Ron T Gansevoort, Stephan J Bakker, Pim van der Harst, Dorine W Swinkels, Peter van der Meer
Journal: Circulation (2014)

Introduction: Iron status and iron-regulatory hormone hepcidin have found to be associated with cardiovascular disease and established heart failure (HF). However, their role in the development of new onset HF in currently unknown. This study sought to investigate the association of iron status and hepcidin levels with new onset HF in the community. Methods: In 6471 subjects from the Prevention of REnal and Vascular ENd-stage Disease (PREVEND), a prospective, community-based, cohort study, we analyzed the association between serum hepcidin, parameters of iron status (ferritin, transferrin saturation) and the risk for new onset HF. Results: Mean age was 53±12 years and 49.3% were male. Median hepcidin concentration was 3.06 (1.67-4.97) nM, median ferritin level was 97 (48-172) ug/L and mean transferrin saturation was 24.8±9.4% (all lower in women; all P<0.001). During a median follow-up of 8.3 years [IQR 7.8-8.9], 203 subjects (3.1%) were newly diagnosed with HF. Per increasing hepcidin or ferritin quintil...
ABC of antithrombotic therapy: Antithrombotic strategies in acute coronary syndromes and percutaneous coronary interventions
Authors: D. L Connolly
Journal: BMJ (2002)

All patients suspected of having acute coronary syndrome should be managed as medical emergencies and monitored in the critical care unit. Baseline tests must include 12 lead electrocardiography, chest x ray examination, and venous blood samples for analyses of haemoglobin and markers of myocardial damage, preferably cardiac troponin T or I.

#### High and low risk patients with suspected acute coronary syndromes

##### High risk

##### Low risk

### Initial management

#### Assessment

Patients with persistent ST segment elevation on 12 lead electrocardiography need immediate reperfusion treatment (thrombolysis or intervention). Patients with ST segment depression, inverted T waves, or pseudonormalisation of T waves on the electrocardiogram, but with a clinical history suggesting cardiac ischaemia should receive initial treatment for angina.

This would include aspirin 300 mg followed by a low dose of 75-150 mg daily. In cases of aspirin intolerance, clopidogrel should be used. β Blockers and nitrates should also be given. Rate limiting calcium antagonists can be used if β blockers are contraindicated or are already being used. Ideally, patients should be given low molecular weight heparin (enoxaparin) according to their weight. If low molecular weight heparin is unavailable, unfractionated heparin may be used. A bolus of 5000 U is given, followed by an infusion adjusted to get an activated partial thromboplastin time (APTT) ratio of 1.8 to 2.5. In light of data from the CURE and PCI-CURE study, clopidogrel (given for at least one month …
HEART FAILURE: THE RELATION OF SYMPTOMS AND SIGNS TO ITS SEVERITY AND DURATION
Authors: W DOCK
Journal: Annals of Internal Medicine (1948)

Article1 July 1948HEART FAILURE: THE RELATION OF SYMPTOMS AND SIGNS TO ITS SEVERITY AND DURATIONWILLIAM DOCK, M.D., F.A.C.P.WILLIAM DOCK, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-29-1-11 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptWhen the estimation of arterial pressure became a routine clinical method, it was at once noted that in cases of congestive heart failure, or cardiac decompensation, arterial pressure often remained abnormally high up to the time of death. Indeed, Sahli noted that in some patients a rise in arterial pressure occurred with the development of failure and that a fall resulted from treatment successfully directed to restoring cardiac compensation.1It also was apparent on the most superficial study of elderly patients with heart failure precipitated by Graves' disease that the total volume flow of blood under basal conditions must be...Bibliography1. SAHLI H: Herzmittel und Vasomotormittel, Verhandl. deutsch. Kong. f. inn. Med., 1901, xix, 45-54. Google Scholar2. BURWELLDEXTER SL: Cardiac output in a case of beriberi, Trans. Assoc. Am. Phys., 1947, lx, 59-64. Google Scholar3. MCMICHAEL J: Circulatory failure studied by means of venous catheterization. Advances in Internal Medicine, Interscience Publishers, New York, 1947, ii, 60-101. Google Scholar4. TARANSZILAGYI LMM: Duration of electrical systole in acute rheumatic carditis in children, Am. Heart Jr., 1947, xxxiii, 14-26. CrossrefGoogle Scholar5. NATHANSONELEK MASR: The influence of heart size on circulation time, Am. Heart Jr., 1947, xxxiii, 464-476. CrossrefGoogle Scholar6. BRUNKNUDSENRAASCHOU CEOF: Kidney function and circulatory collapse, Jr. Clin. Invest., 1947, xxv, 568-574. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brooklyn, New York*Received for publication November 1, 1947.From the Department of Medicine, Long Island College of Medicine, Brooklyn, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCardiovascular SystemPartial extracorporeal circulation in acute heart failureAberrant atrioventricular conduction with normal P-R interval and prolonged QRS complex simulating bundle branch blockStudies on Congestive Circulatory FailureExperimental Hypervolemic Heart Failure: Its Bearing on Certain General Principles of Heart FailurePathophysiologie der HerzinsuffizienzTreatment of Heart Failure 1 July 1948Volume 29, Issue 1Page: 11-21KeywordsBlood pressureBlood volumeElderlyFallsHeart diseasesHeart failureLongitudinal studiesSigns and symptoms ePublished: 1 December 2008 Issue Published: 1 July 1948 PDF downloadLoading ...
Changes in Lymphocyte Activity after Thermal Injury
Authors: Carol L. Miller, Christopher C. Baker
Journal: Journal of Clinical Investigation (1979)

The high incidence of fatal septicemia associated with severe thermal injury is believed to result from a loss of immunocompetence. To detect burn-mediated immune defects, lymphocyte function in peripheral blood leukocytes from 18 individuals sustaining 20-80% full thickness thermal burns was investigated. We examined the kinetics of the mitogen responses, the development of suppressive activity, and the correlation of mononuclear cell functional abnormalities with the incidence of sepsis. Patients were divided into three groups corresponding to their clinical course. The phytohemagglutinin responses of Ficoll-Hypaque purified leukocytes from eight of these patients (group III) were normal at day 1-2 after injury, but were significantly depressed (mean 16% of normal) at days 5-10 after injury. All of these group III patients experienced multiple, severe, septic episodes, and septic mortality was 75%. The other 10 burned individuals showed either augmented (group II) or unaltered (group I) mitogen responsiveness.
Developmental and Functional Role of Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Isoforms in Normal Human Fetal Pituitary, L beta T2 Gonadotropes and Zebrafish Neuroendocrine Tissues.
Authors: A. C. Chand, I. R. Thompson, S. E. Akbareian, S. Toro, Richard Anderson, Alan McNeilly, I. M. McGonnell, R. C. Fowkes
Journal: Endocrine Reviews (2010)
Bellini Near Paris (1835)
Authors: Floyd Skloot
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PAROXYSMAL HEMOGLOBINURIA WITH REPORT OF A CASE
Authors: A. C. Woofter, B. S. Parks
Journal: Annals of Internal Medicine (1938)

Case Reports1 September 1938PAROXYSMAL HEMOGLOBINURIA WITH REPORT OF A CASEA. C. WOOFTER, B.S., M.D., B. S. PARKS, M.D., M.Sc.A. C. WOOFTER, B.S., M.D.Search for more papers by this author, B. S. PARKS, M.D., M.Sc.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-12-3-402 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe term "hemoglobinuria" is used to designate the excretion of blood pigment in the urine with total absence of red blood cells, or with only a relatively small number that cannot be considered sufficient to explain the altered, bloody or dark blood like, appearance of the specimen.This phenomenon is observed: (1) when hemoglobin in sufficient quantity is injected into the blood stream; (2) after procedures resulting in solution of the red blood cells, such as transfusion of blood, or the injection intravenously of incompatible blood serum of another species, of distilled water, glycerine, oil or many other chemical substances;... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Parkersburg, West Virginia*Received for publication January 18, 1935. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDie hämolytischen AnämienSerologie und Klinik der autoimmunhämolytischen Erkrankungen 1 September 1938Volume 12, Issue 3Page: 402-406KeywordsBlood cellsBlood transfusionExcretionHemoglobinOilsRed blood cellsRiversUrine ePublished: 1 December 2008 Issue Published: 1 September 1938 PDF downloadLoading ...
Abstract #LB-259: A pilot study utilizing molecular profiling of patients\#8217; tumors to find potential targets and select treatments for their refractory cancers
Authors: Daniel Von Hoff, Joseph Stephenson, Peter Rosen, David Loesch, Mitesh Borad, Stephen Anthony, Katrina Schroeder, Ranay Yarian, Susan Brown, Nina Cantafio, Jeremy Hon, Donald Richards, Lon Smith, David Agus, Tom Fitch, Ernesto Wasserman, Cristian Fernanadez, Sylvan Green, Michael Bittner, Arlet Alarcon, David Mallery, Robert Penny
Journal: Cancer Research (2009)

Introduction:  Unfortunately, the majority of patients with metastatic cancer eventually run out of treatment options for their tumors. This prospective study was designed to determine whether molecular profiling of patients\#8217; tumors at this stage in their disease could provide any clinical benefit.  Methods:  To be eligible, patients must have metastatic cancer and at least two prior lines of systemic therapy, have measurable or evaluable disease, have clear documentation of progression on their last treatment prior to study entry, and undergo or have available a tumor biopsy for molecular profiling. Patients\#8217; tissue samples were submitted for molecular profiling in two formats, including formalin-fixed for immunohistochemistry assays and immediately frozen tissue for oligonucleotide microarray gene expression assays. The primary objective was to compare progression free survival (PFS) using a treatment regimen selected by molecular profiling with the PFS for the most recent regimen on which the patient progressed (i.e., patients were their own controls). The molecular profiling approach was deemed of clinical benefit for the individual patient who had a PFS ratio (PFS on molecular profiling selected therapy/PFS on prior therapy) of \#8805;1.3.  Results:  Nine sites in the U.S. submitted tumor samples. Of 86 patients, 66 received treatment based on molecular profiling. The results of patients treated with a regimen selected by molecular profiling are outlined in Table 1 below.  Conclusion:  This prospective study demonstrated that: a) it is possible to measure molecular targets in patients9 tumors from nine different centers; and b) this approach may provide clinical benefit for some patients (provide a longer PFS treated by molecular profiling results than the PFS they had on their prior treatment regimen). Supported by a grant from the Stardust Foundation. >$$table_{24A86976-7E01-48CD-B1FF-14EBA7D6B8A3}$$ >   Citation Information:  In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-259.
Abstract P183: FTO Genotype, Dietary Protein, and Change in Appetite: the Pounds Lost trial
Authors: Tao Huang, Qibin Qi, Yanping Li, Frank Hu, George A Bray, Frank M Sacks, Lu Qi
Journal: Circulation (2014)

Objective: A common "obesity-risk" variant rs9939609 in the FTO gene was recently found to affect appetite, and the gene is sensitive to regulation of amino acids. We examined the interaction between FTO genotype and protein intake on the long-term changes in appetite in a randomized controlled trial. Research Design and Methods: We genotyped FTO rs9939609 in 737 overweight adults in the 2-year Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial and assessed four appetite related traits including cravings, fullness, hunger, and prospective consumption. Results: We found that dietary protein significantly modified genetic effects on changes in food cravings at 6 months, after adjustment for age, sex, ethnicity, baseline body mass index, weight change, baseline value for food cravings (P for interaction=0.027). The A allele was associated with a greater decrease in food cravings among the participants with high protein diet intake (P=0.027), but not in those low protein diet group (P= 0.384). Weight regain from 6 months to 24 months attenuated the gene-protein interactions. Protein intakes did not modify the FTO genotype effects on other appetite measures. Conclusions: Our data suggest that individuals with the FTO rs9939609 A allele might obtain more benefits in reduction of food cravings by choosing a hypocaloric and higher protein weight-loss diet. Keywords: diet, genetic variation, food cravings, gene-diet interaction, weight-loss trial
LEIOMYOSARCOMA OF THE SMALL BOWEL IN A CHILD
Authors: D B MONHEIT, G A DEGENSHEIN
Journal: Annals of Internal Medicine (1955)

Case Reports1 October 1955LEIOMYOSARCOMA OF THE SMALL BOWEL IN A CHILDDAVID B. MONHEIT, M.D., GEORGE A. DEGENSHEIN, M.D.DAVID B. MONHEIT, M.D.Search for more papers by this author, GEORGE A. DEGENSHEIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-4-903 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptIn the past 10 years an ever increasing number of small bowel tumors has been reported in the literature. This is undoubtedly due in part to improved diagnostic technics and to a willingness to intervene surgically in cases of gastrointestinal bleeding with negative roentgenograms.Since the number of small bowel sarcomas remains modest and the literature has been reviewed adequately by others, it seems hardly warranted merely to add another single case history to an already cluttered literature. However, in the case to be reported there are several instructive features: the age of the patient, the disturbing red herring of...Bibliography1. BoydMersheimerNightingale LJWLEJ: Diagnosis of intestinal neoplasms, J. M. Soc. New Jersey 48: 474-482 (Oct.) 1951. MedlineGoogle Scholar2. Maingot R: Textbook on abdominal operations, 1949, Appleton-Century-Crofts, New York. Google Scholar3. Nuessle RF: Tumors of the small bowel, Journal Lancet 73: 12-15 (Jan.) 1953. Google Scholar4. RameyFabb PMKS: Lesions of the small intestine, S. Clin. North America 32: 1457-1473 (Oct.) 1952. CrossrefGoogle Scholar5. Root JC: Roentgenologic diagnosis of tumors of the small intestine, M. Clin. North America 32: 436-442 (Mar.) 1948. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Brooklyn, N. Y.*Received for publication August 16, 1954. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCongenital gastrointestinal stromal tumour is morphologically indistinguishable from the adult form, but does not express CD117 and carries a favourable prognosisLéiomyosarcome primitif de l'intestin greˆle chez l'enfantIntussusception and leiomyosarcoma of the gastrointestinal tract in a pediatric patientPrinciples in the management of pediatric intestinal leiomyosarcomasIntestinal leiomyosarcoma in childhood—Case report and review of the literatureCase 1-1980LEIOMYOSARCOMA OF THE DUODENUMSmooth muscle tumors in childrenLeiomyosarcoma of the Small IntestineTumors of the Gastrointestinal Tract and Pancreas 1 October 1955Volume 43, Issue 4Page: 903-907KeywordsHemorrhageSarcoma ePublished: 1 December 2008 Issue Published: 1 October 1955 PDF downloadLoading ...
Discriminating borderline personality disorder from other axis II disorders
Authors: M C Zanarini, J G Gunderson, F R Frankenburg, D L Chauncey
Journal: American Journal of Psychiatry (1990)

The authors used the Revised Diagnostic Interview for Borderline Patients to assess 22 clinical features of 120 patients with borderline personality disorder and 103 control subjects with other axis II disorders. Four of the 22 features were common in but nondiscriminating for borderline disorder, 11 were discriminating for but nonspecific to borderline disorder, and seven were more specific to borderline disorder. The authors conclude that many clinical features thought to be indicative of borderline disorder are better viewed as personality disorder traits and that the seven more specific features, alone or in conjunction with one another, may be particularly useful markers for borderline personality disorder.
Abstract 4133: Disparities in colon cancer survival according to payer status: Findings from national cancer data bank
Authors: Srinivas S. Devarakonda, Runhua Shi, Amarendra Neppalli, Glenn Mills
Journal: Cancer Research (2014)

Abstract BACKGROUND: The objective of the current study was to examine the impact of payer status on relative survival outcomes in colon cancer patients. METHODS: A population-based analysis of National Cancer Data Bank (NCDB) records for invasive colon cancer was done using data from patients diagnosed between 1998 and 2006 and followed up to 2011. The cohort consisted of colon cancer patients of analytic stage I to stage IV. Information regarding age, race, gender, stage of cancer at the time of diagnosis, year of diagnosis, insurance status, income, treatment received and diagnostic facility, and type of treating facility were included in this study. Age, sex, race, calendar year specific US life table between 1970 and 2007 were used to compute expected survival. Multivariate Poisson modeling was used to estimate relative survival for payer status adjusting for other factors. RESULTS: 436,235 colon cancer patients who met the inclusion criteria were included in the study. The mean age at diagnosis was 68.9 years. The stage distribution among the variables listed above is statistically significant. The 5-year cumulative relative survivals are 0.76, 0.84, 0.93, 1.74 and 1.10 for uninsured, Medicaid, private insurance, Medicare, and unknown payer status respectively. In multivariate analysis of relative survival, adjusting for other factors, the excess hazard ratios (EHR) were 1.74, 1.14, 0.89 and 1.29 for uninsured, Medicaid, Medicare, and unknown payer status versus private insurance respectively (P&amp;lt;0.05). The EHRs for blacks and other races versus whites were 1.07 and 1.53 respectively (p&amp;lt;0.05). The EHRs for follow-up year of 2, 3, 4, 5 versus year 1 were 1.17, 0.21, 0.18, and 0.54 respectively (P &amp;lt;0.05). Compared to academic/research program facility type, the EHRs for community cancer program, comprehensive community cancer program, and other specified types of cancer programs were 1.02,0.77 and 25.9 respectively (P &amp;lt;0.05). The relative survival rates for stage II, III, IV versus stage I were 0.95, 0.82, and 0.70 respectively (P&amp;lt;0.05). Diagnosis before or after 2002 and the type of treatment facility lead to a marginal difference in the relative survival. CONCLUSIONS: Our study shows the impact of payer status on the relative survival of patients with colon cancer and demonstrated increased mortality for uninsured patients in contrast to survival benefit for patients with Medicare and private insurance. Citation Format: Srinivas S. Devarakonda, Runhua Shi, Amarendra Neppalli, Glenn Mills. Disparities in colon cancer survival according to payer status: Findings from national cancer data bank. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4133. doi:10.1158/1538-7445.AM2014-4133